Tagged with Pharm

Pharma Legal Handbook All legal aspects surrounding localization in Bulgaria. Prepared in association with Kinstellar and PharmDedict, this is an extract from The Pharma Legal Handbook: Bulgaria, available to purchase here for GBP 75. 1. Are there any rules or regulations requiring and/or encouraging localization in your country? What is the legal framework…

Pharma Legal Handbook All legal aspects surrounding localization in Bulgaria. Prepared in association with Kinstellar and PharmDedict, this is an extract from The Pharma Legal Handbook: Bulgaria, available to purchase here for GBP 75. 1. Are biosimilar medicines considered the same as generic medicines in your country? In order to be considered generic…

Switzerland After an illustrious career in oncology R&D, contributing greatly to the development of cutting-edge cancer therapies at Novartis and Gilead, Alessandro Riva, MD joined biotech Ichnos Sciences as its founding CEO in 2019. In a recent conversation with PharmaBoardroom, Riva explained why he took on this unique new opportunity at…

UK The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical company successfully listed on NASDAQ, raising over USD 30 million. Founded in 1998, UK headquartered GW Pharma is a true pioneer as the company behind Epidiolex, the world’s first prescription medicine…

Switzerland This article forms part of Healthcare & Life Sciences Review: Switzerland February 2021, a comprehensive up-to-date country report on the Swiss pharma market, featuring data snapshots, feature articles, exclusive interviews and more. Click here to download.   Long heralded as an innovation powerhouse able to hold its own against the…

Switzerland In a wide-ranging interview CEO Bertrand Ducrey introduces Debiopharm’s unique business focus on drug improvement, drug delivery, and drug targeting; recent progress in oncology, including an FDA breakthrough designation and out-licensing deal for its head and neck cancer product; as well as a host of other topics, including the company’s…

Europe The full list of medicines recommended for approval by the European Medicines Agency (EMA) in 2020 divided by therapeutic area and with drugs that contained a new active substance highlighted in bold. The EMA approved a raft of new oncology medicines in 2020, as well as new treatments in haematology/…

Japan Following on from our recent compilations of 2020 new drug approvals in the USA, China, and Switzerland, see below for the Japanese PMDA’s new drug approvals list for April-October 2020. Made with Visme Infographic Maker  

China The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment news on Clover Biopharmaceuticals, Sciwind Biosciences, and Gensciences.   AstraZeneca signs deal with Chinese biotech Junshi Biosciences to market anti-PD-1 cancer drug in China https://www.biopharma-reporter.com/Article/2021/03/01/AstraZeneca-betting-on-China-s-PD-1-cancer-market AstraZeneca has signed a…

Switzerland After 15 years as director at the Friedrich Miescher Institute for Biomedical Research (FMI) (2004-2019) and even longer as the group leader at her own research lab, Professor Susan M. Gasser was appointed director of the Foundation of the Swiss Institute for Experimental Cancer (ISREC), in a way closing the…

Switzerland Dipharma SA is a Swiss specialty pharmaceutical company, developing improved generics medicines for rare metabolic diseases. Founder & CEO Marc-Olivier Geinoz discusses why the company has chosen to compete in the largely unexplored rare diseases generics space, its direct presence in the German market, and the opportunities inherent in metabolic…

China The Chinese NMPA’s drug approval list for 2020 includes a surge in approvals for locally developed drugs. A total of 46 new drugs were approved in 2020 (less than the 53 approved in 2019), including 28 chemical drugs and 18 biological products. Read more analysis from Xu Wang of Novo…